News

AAN 2025: Less off time, more good on time with long-term Onapgo

Treatment for up to three years with Onapgo (apomorphine hydrochloride) — approved in the U.S. earlier this year as an add-on therapy for advanced Parkinson’s disease — significantly and sustainably reduced off time, when symptoms are not fully controlled, in adults with the neurodegenerative condition. Importantly, the researchers…

Excess exercise may worsen Parkinson’s symptoms, report says

Although physical exercise has well-established benefits for people with Parkinson’s disease, too much of it may worsen fatigue and motor symptoms, according to a report of two cases in the U.K. Both patients believed that intense exercise could help them overcome the disease, including reversing the degeneration of dopaminergic…

AAN 2025: Tavapadon offers rapid, sustained motor benefits

Tavapadon, an orally available small molecule being developed for Parkinson’s disease, was generally safe and eased motor symptoms within one month of being administered at either a fixed or flexible dose to adults with early-stage disease. It also reduced the risk of common side effects typically associated with similar classes…

AAN 2025: Vyalev has good long-term safety profile in Parkinson’s

Vyalev (foscarbidopa and foslevodopa) demonstrated a favorable long-term safety and tolerability profile, along with sustained motor symptom control, in Parkinson’s disease patients who participated in the extension part of a Phase 3 trial (NCT03781167). Results from nearly two years of the extension study (NCT04379050) showed…